



# Vista Pharmaceuticals Ltd

CIN : L24239TG1991PLC012264

7-1-212/A/70, Plot No. : 85, Shivbagh, Ameerpet, Hyderabad-16. Telangana

India Tel: 91-40-65581585, Fax : 91-40-23741585

e-mail : admin.hyd@vistapharmaceuticals.com www.vistapharmaceuticals.com

Hyderabad, May 30<sup>th</sup>, 2018

To,  
The General Manager,  
Listing Department,  
Bombay Stock Exchange Limited,  
1<sup>st</sup> Floor, New Trading Wing,  
Rotunda Building, P.J. Towers,  
Dalal Street Fort,  
Mumbai-400001.

Dear Sir/Ma'am,

**Sub:** Outcome of Board Meeting – Regulation 30.

**Ref:** Company Scrip Code: 524711

With reference to the subject cited, it is hereby informed that the Board of Directors of the Company at its Meeting held on Wednesday, 30th May, 2018 at 04:30 PM, at the corporate office of the Company to *inter-alia* considered and approved the following:

1. Audited financial statements of the Company as per Indian Accounting Standard (INDAS) for the quarter and financial year ended 31<sup>st</sup> March, 2018.
2. Draft Auditor's Report on the financial statements of the Company for the financial year ended 31<sup>st</sup> March, 2018.
3. Appointment of
  - a) V. Durga Prasad & Associates, Chartered Accountants as Internal Auditors of the Company for the FY 2017-18.
  - b) Secretarial Auditor of the Company for the FY 2017-18.

Kindly take the same on record and acknowledge the receipt of the same.

Thanking You,  
**for Vista Pharmaceuticals Limited**

**SD/-**

**Chalapathirao Venkata Naraparaju**

**Wholetime Director**

**DIN: 03270178**



# Vista Pharmaceuticals Ltd

CIN : L24239TG1991PLC012264

7-1-212/A/70, Plot No. : 85, Shivbagh, Ameerpet, Hyderabad-16. Telangana

India Tel: 91-40-65581585, Fax : 91-40-23741585

e-mail : admin.hyd@vistapharmaceuticals.com www.vistapharmaceuticals.com

Hyderabad, May 30<sup>th</sup>, 2018

To  
The General Manager,  
Listing Department,  
Bombay Stock Exchange Limited,  
1<sup>st</sup> Floor, New Trading Wing,  
Rotunda Building, P.J. Towers,  
Dalal Street Fort,  
Mumbai- 400001.

Dear Sir/Ma'am,

**Sub:** Financial Results for the quarter and year ended 31<sup>st</sup> March, 2018 – Regulation 33 (3) (a).

**Ref:** Company Scrip Code: 524711

With reference to the subject cited, it is hereby informed that the Board of Directors of the Company at its meeting held on Wednesday, 30<sup>th</sup> May, 2018 at 04.30 P.M. at the Corporate office of the Company, interalia, considered and approved the audited Financial Results for the quarter and year ended 31<sup>st</sup> March, 2018.

Copy of audited Financial Results for the quarter and year ended 31<sup>st</sup> March, 2018, along with Statement of Assets and Liabilities and Audit Report is enclosed herewith.

Kindly take the same on record and acknowledge the receipt of the same.

Thanking You,  
*for Vista Pharmaceuticals Limited*

SD/-

**Chalapathirao Venkata Naraparaju**  
**Wholetime Director**  
**DIN: 03270178**



# Vista Pharmaceuticals Ltd

CIN : L24239TG1991PLC012264

7-1-212/A/70, Plot No. : 85, Shivbagh, Ameerpet, Hyderabad-16. Telangana

India Tel: 91-40-65581585, Fax : 91-40-23741585

e-mail : admin.hyd@vistapharmaceuticals.com www.vistapharmaceuticals.com

Hyderabad, 30<sup>th</sup> May, 2018.

To  
The General Manager,  
Listing Department,  
Bombay Stock Exchange Limited,  
1<sup>st</sup> Floor, New Trading Wing,  
Rotunda Building, P.J. Towers,  
Dalal Street Fort,  
Mumbai-400001.

Dear Sirs/Madam,

**Subject:** Declaration pursuant to Regulation 33 (3) (d) of the Securities & Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2016.

## DECLARATION

I, Chalapathirao Venkata Naraparaju, Wholetime Director of the Vista Pharmaceuticals Limited (CIN: L24239TG1991PLC012264) having its Registered office at Plot Nos.10 TO 14 and 16 To 20, APIIC, Industrial Estate, Chityal, Gopalaipalli 508254, Telangana, India hereby declare that, the Statutory Auditors of the Company, M/s. MAHESH, VIRENDER & SRIRAM (FRN: 001939S), have issued an Audit Report with unmodified opinion on the annual Audited Financial Results of the Company for year ended on 31<sup>st</sup> March, 2018.

This Declaration is given in compliance to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended by the SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulation, 2016 vide notification No. SEBI/LAD-NRO/GN/2016-17/001 dated May 25, 2016 and Circular no. CIR/CFD/CMD/56/2016 dated May 27, 2016.

Kindly take this declaration on your records.

Yours Sincerely,

Thanking You,  
for **Vista Pharmaceuticals Limited**

Sd/-

**Chalapathirao Venkata Naraparaju**

**Wholetime Director**

**DIN: 03270178**



# Vista Pharmaceuticals Ltd

CIN : L24239TG1991PLC012264

7-1-212/A/70, Plot No. : 85, Shivbagh, Ameerpet, Hyderabad-16. Telangana

India Tel: 91-40-65581585, Fax : 91-40-23741585

e-mail : admin.hyd@vistapharmaceuticals.com www.vistapharmaceuticals.com

## VISTA PHARMACEUTICALS LIMITED

CIN:L24239TG1991PLC012264

### Audited financial results for the Quarter and Year ended 31.03.2018

(in Rs Lakhs)

S.No	Particulars	Quarter ended			Year ended	
		March 31,2018	December 31,2017	March 31,2017	March 31,2018	March 31,2017
		Audited	Un Audited	Audited	Audited	Audited
<b>1</b>	<b>Income</b>					
	a. Revenue from operations	710.78	711.59	611.53	2891.78	2418.19
	b. Other income	39.68	-	5.31	39.68	5.74
<b>2</b>	<b>Total Income (a+b)</b>	<b>750.46</b>	<b>711.59</b>	<b>616.84</b>	<b>2931.46</b>	<b>2423.93</b>
<b>3</b>	<b>Expenses</b>					
	a) Cost of Material Consumed	415.27	370.31	363.36	1596.27	1610.27
	b) Change in Inventories	-	-	-	-	-
	c) Employee benefits expense	33.98	26.68	31.49	105.40	87.65
	d) Finance costs	40.19	38.18	25.05	157.49	87.60
	e) Depreciation and amortization expense	22.49	56.04	23.80	133.56	101.51
	f) Other expenses	174.14	148.49	153.79	656.04	414.66
	<b>Total Expenses</b>	<b>686.08</b>	<b>639.70</b>	<b>597.48</b>	<b>2,648.77</b>	<b>2,301.68</b>
<b>4</b>	<b>Profit before tax (2-3)</b>	<b>64.38</b>	<b>71.89</b>	<b>19.36</b>	<b>282.69</b>	<b>122.25</b>
<b>5</b>	<b>Tax expense</b>					
	(1) Current tax	13.13	14.66	6.76	57.64	6.76
	(2) Deferred tax	(6.40)	(2.22)	(2.31)	6.41	(9.26)
<b>6</b>	<b>Net Profit for the Period (4-5)</b>	<b>57.66</b>	<b>59.45</b>	<b>14.92</b>	<b>218.65</b>	<b>124.75</b>
<b>7</b>	<b>Other comprehensive income (OCI)</b>					
	(a) (i) Items that will not be reclassified to profit or loss	-	-	-	-	-
	(ii) Tax on items that will not be reclassified to profit or loss	-	-	-	-	-
	(b) (i) Items that will be reclassified to profit or loss	-	-	-	-	-



## Vista Pharmaceuticals Ltd

CIN : L24239TG1991PLC012264

7-1-212/A/70, Plot No. : 85, Shivbagh, Ameerpet, Hyderabad-16. Telangana

India Tel: 91-40-65581585, Fax : 91-40-23741585

e-mail : admin.hyd@vistapharmaceuticals.com www.vistapharmaceuticals.com

	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
	<b>Total Other Comprehensive income</b>	-	-	-	-	-
8	<b>Total Comprehensive income (6+7)</b>	<b>57.66</b>	<b>59.45</b>	<b>14.92</b>	<b>218.65</b>	<b>124.75</b>
	<b>Earnings per equity share</b> (Face value of Rs.10/- each)					
	(1) Basic	0.20	0.21	0.05	0.76	0.46
	(2) Diluted	0.19	0.20	0.05	0.73	0.46
	Paid- up equity share capital(Face Value of Rs.2/- each)	582.94	572.94	531.43	582.94	531.43



# Vista Pharmaceuticals Ltd

CIN : L24239TG1991PLC012264

7-1-212/A/70, Plot No. : 85, Shivbagh, Ameerpet, Hyderabad-16. Telangana

India Tel: 91-40-65581585, Fax : 91-40-23741585

e-mail : admin.hyd@vistapharmaceuticals.com www.vistapharmaceuticals.com

<b>VISTA PHARMACEUTICALS LIMITED</b>		
<b>CIN:L24239TG1991PLC012264</b>		
<b>STATEMENT OF ASSETS AND LIABILITIES</b>		
	<b>(Rs. In lakhs)</b>	
<b>Particulars</b>	<b>As at 31st March 2018</b>	<b>As at 31st March 2017</b>
	<b>(Audited)</b>	<b>(Audited)</b>
<b>ASSETS</b>		
<b>Non-current assets</b>		
(a) Property, Plant and Equipment	1,193.16	976.20
(b) Capital work-in-progress	710.94	199.16
(c) Goodwill	-	-
(d) Other Intangible assets	573.65	369.66
(e) Financial Assets	-	-
(i) Investments	1.98	0.05
(ii) Loans	7.86	6.66
(iii) Other financial assets	-	-
(f) Tax Assets	28.74	59.64
(g) Other Non-Current Assets	-	0.64
<b>Total Non - Current Assets</b>	<b>2,516.33</b>	<b>1,612.01</b>
<b>Current assets</b>		
(a) Inventories	1,091.23	814.27
(b) Financial assets		
(i) Investments	-	-
(ii) Trade receivables	1,086.13	901.32
(iii) Cash and Bank equivalents	97.68	190.75
cash and cash equivalent (restricted cash)	81.10	383.28
(iv) Others	-	2.63
(c) Other current assets	427.67	257.98
<b>Total Current Assets</b>	<b>2,783.82</b>	<b>2,550.23</b>
<b>Total Assets</b>	<b>5,300.15</b>	<b>4,162.24</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
(a) Equity Share capital	582.94	531.43



## Vista Pharmaceuticals Ltd

CIN : L24239TG1991PLC012264

7-1-212/A/70, Plot No. : 85, Shivbagh, Ameerpet, Hyderabad-16. Telangana

India Tel: 91-40-65581585, Fax : 91-40-23741585

e-mail : admin.hyd@vistapharmaceuticals.com www.vistapharmaceuticals.com

<b>(b) Money received against warrants</b>	<b>556.93</b>	<b>-</b>
<b>(c) Other equity</b>	<b>2,045.87</b>	<b>1,129.48</b>
<b>Total Equity</b>	<b>3,185.75</b>	<b>1,660.91</b>
<b>Liabilities</b>		
<b>Non-current liabilities</b>		
<b>(a) Financial Liabilities</b>		
<b>(i) Borrowings</b>	<b>588.43</b>	<b>602.97</b>
<b>(ii) Other financial liabilities</b>	<b>-</b>	<b>-</b>
<b>(b) Deferred tax liabilities (Net)</b>		<b>-</b>
<b>(c) Long term Provisions</b>	<b>6.09</b>	<b>5.23</b>
<b>Total Non - Current Liabilities</b>	<b>594.53</b>	<b>608.19</b>
<b>Current liabilities</b>		
<b>(a) Financial Liabilities</b>		
<b>(i) Borrowings</b>	<b>518.02</b>	<b>530.43</b>
<b>(ii) Trade payables</b>	<b>918.06</b>	<b>1,303.44</b>
<b>(iii) Other financial liabilities</b>	<b>13.49</b>	<b>17.13</b>
<b>(b) Other current liabilities</b>	<b>12.66</b>	<b>17.64</b>
<b>(c) Provisions</b>	<b>57.64</b>	<b>24.50</b>
<b>Total Current Liabilities</b>	<b>1,519.87</b>	<b>1,893.13</b>
<b>Total Liabilities</b>	<b>2,114.40</b>	<b>2,501.33</b>
<b>Total Equity and Liabilities</b>	<b>5,300.15</b>	<b>4,162.24</b>



## Vista Pharmaceuticals Ltd

CIN : L24239TG1991PLC012264

7-1-212/A/70, Plot No. : 85, Shivbagh, Ameerpet, Hyderabad-16. Telangana

India Tel: 91-40-65581585, Fax : 91-40-23741585

e-mail : admin.hyd@vistapharmaceuticals.com www.vistapharmaceuticals.com

### Notes to the Statement of financial Results

1. The financial results of the company have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under the companies (Indian accounting standards) Rules, 2015 as amended by the companies (Indian accounting standards) (Amendment) rules, 2016. The company adopted Ind As from 1st April 2017, and these are the company's first annual financial statements prepared in accordance with Indian Accounting Standards (Ind AS). The company has adopted all applicable standards and adoptions were carried out in accordance with Ind AS 101- First time adoption of Indian accounting Standards.
2. Total Income for the current quarter is Rs.750.46 Lakhs compared to Rs.616.84 Lakhs for the corresponding quarter of the previous year. Total Income for the financial year ended 31st March 2018 is Rs.2931.46 Lakhs compared to Rs.2423.93 Lakhs for the previous year.
3. The Profit before tax for the current quarter is Rs. 64.38 Lakhs compared to Rs. 19.35 Lakhs for the corresponding quarter of the previous year. The Profit before tax for the financial year ended 31st March 2018 is Rs. 282.69 Lakhs compared to Rs. 122.26 Lakhs for the previous year.
4. The Profit/(Loss) After tax for the current quarter is Rs.57.66 Lakhs compared to Rs.14.90 Lakhs for the corresponding quarter of the previous year. The Profit/(Loss) after tax for the financial year ended 31st March 2018 is Rs.218.65 Lakhs compared to Rs.124.76 Lakhs for the previous year
5. (a) Reconciliation between Standalone financial results, as previously reported (referred as Previous GAAP) and IND AS for the quarter and Financial year ended 31st March 2017 as under





## Vista Pharmaceuticals Ltd

CIN : L24239TG1991PLC012264

7-1-212/A/70, Plot No. : 85, Shivbagh, Ameerpet, Hyderabad-16. Telangana

India Tel: 91-40-65581585, Fax : 91-40-23741585

e-mail : admin.hyd@vistapharmaceuticals.com www.vistapharmaceuticals.com

	<b>Quarter ended 31st March 2017</b>	<b>Year ended 31st March 2017</b>
<b>Particulars</b>	<b>(Audited)</b>	<b>(Audited)</b>
<b>Net profit as per Previous GAAP</b>	<b>10.07</b>	<b>115.14</b>
a) Impact on account of measuring long term borrowings using effective rate of Interest	8.08	8.08
b) Impact on account of Expected Credit Loss	(0.61)	(0.94)
c) Items considered as amortisation expense in the P& L as per previous GAAP already adjusted in opening equity as on the transition to IND AS.	1.81	2.48
d) Impact on account of Current & Deferred Taxes	(4.45)	(0.01)
<b>Net profit as per IND AS</b>	<b>14.90</b>	<b>124.75</b>
a) Impact on account of measuring investments at fair value through OCI		
<b>Total Comprehensive Income under IND AS</b>	<b>14.90</b>	<b>124.75</b>

- b) Reconciliation between Total Equity, as previously reported (referred as Previous GAAP) and IND AS for the quarter and Financial year ended 31st March 2017 and 1st April 2016 as under

	<b>Equity as at 31st March 2017</b>	<b>Equity as at 1st April 2016</b>
<b>Particulars</b>	<b>(Audited)</b>	<b>(Audited)</b>
<b>Equity as per Previous GAAP</b>	<b>1,614.03</b>	<b>1,121.00</b>
Items not qualified as asset as per IND AS	-9.93	-9.93
Impact on account of deferred Tax	50.38	50.39
Impairment of Receivables	-4.13	(3.19)



## Vista Pharmaceuticals Ltd

CIN : L24239TG1991PLC012264

7-1-212/A/70, Plot No. : 85, Shivbagh, Ameerpet, Hyderabad-16. Telangana

India Tel: 91-40-65581585, Fax : 91-40-23741585

e-mail : admin.hyd@vistapharmaceuticals.com www.vistapharmaceuticals.com

Items considered as amortisation expense in the P& L as per previous GAAP already adjusted in opening equity as on the transition to IND	2.48	-
Impact on account of measuring long term borrowings using effective rate of Interest	8.08	
<b>Equity as per IND AS</b>	<b>1660.91</b>	<b>1158.26</b>

6. The Company concluded that there is only one operating segment i.e, Manufacturing of Pharmaceutical products and the same becomes only one operating and reportable segment the Company. Accordingly, the Company shall present entity-wide disclosures enumerated in paragraphs 32, 33 and 34 of Ind AS 108.
7. The aforementioned results are reviewed by the Audit Committee of the Board and subsequently taken on record by the board of directors at its meeting held on 30th May, 2018. The statement included the results for the quarter ended 31st March 2018 and 31st March 2017 being the balancing figure of the audited figures in respect of the full financial year and the published year to date figures upto the third quarter of the respective financial years, which were subject to limited review by the respective auditors.
8. The results for the year ended 31st March 2018 are also available on the Bombay stock exchange website, the National Stock exchange website and on the Company's website.
9. The company is acquiring a complex ANDA for UROCARE and its US market size is USD 1.3 billion (Rs 8,840 Crores) as per the latest IMS data.
10. The company already filed a complex ANDA in September 2017, targeting Cardialgy segment with a US market size of USD 200 million (Rs 1,360 Crores) as per latest IMS data.



# Vista Pharmaceuticals Ltd

CIN : L24239TG1991PLC012264

7-1-212/A/70, Plot No. : 85, Shivbagh, Ameerpet, Hyderabad-16. Telangana  
India Tel: 91-40-65581585, Fax : 91-40-23741585  
e-mail : admin.hyd@vistapharmaceuticals.com www.vistapharmaceuticals.com

Hyderabad, May 30<sup>th</sup>, 2018

To,  
The General Manager,  
Listing Department,  
Bombay Stock Exchange Limited,  
1<sup>st</sup> Floor, New Trading Wing,  
Rotunda Building, P.J. Towers,  
Dalal Street Fort,  
Mumbai-400001.

Dear Sir/Ma'am,

**Sub:** Outcome of Board Meeting – Regulation 30.

**Ref:** Company Scrip Code: 524711

With reference to the subject cited, it is hereby informed that the Board of Directors of the Company at its Meeting held on Wednesday, 30th May, 2018 at 04:30 PM, at the corporate office of the Company to *inter-alia* considered and approved the following:

1. Audited financial statements of the Company as per Indian Accounting Standard (INDAS) for the quarter and financial year ended 31<sup>st</sup> March, 2018.
2. Draft Auditor's Report on the financial statements of the Company for the financial year ended 31<sup>st</sup> March, 2018.
3. Appointment of
  - a) V. Durga Prasad & Associates, Chartered Accountants as Internal Auditors of the Company for the FY 2017-18.
  - b) Secretarial Auditor of the Company for the FY 2017-18.

Kindly take the same on record and acknowledge the receipt of the same.

Thanking You,  
for Vista Pharmaceuticals Limited

**Chalapathirao Venkata Naraparaju**  
Wholetime Director  
DIN: 03270178





# Vista Pharmaceuticals Ltd

CIN : L24239TG1991PLC012264

7-1-212/A/70, Plot No. : 85, Shivbagh, Ameerpet, Hyderabad-16. Telangana  
India Tel: 91-40-65581585, Fax : 91-40-23741585  
e-mail : admin.hyd@vistapharmaceuticals.com www.vistapharmaceuticals.com

Hyderabad, May 30<sup>th</sup>, 2018

To  
The General Manager,  
Listing Department,  
Bombay Stock Exchange Limited,  
1<sup>st</sup> Floor, New Trading Wing,  
Rotunda Building, P.J. Towers,  
Dalal Street Fort,  
Mumbai- 400001.

Dear Sir/Ma'am,

**Sub:** Financial Results for the quarter and year ended 31<sup>st</sup> March, 2018 – Regulation 33 (3) (a).

**Ref:** Company Scrip Code: 524711

With reference to the subject cited, it is hereby informed that the Board of Directors of the Company at its meeting held on Wednesday, 30<sup>th</sup> May, 2018 at 04.30 P.M. at the Corporate office of the Company, interalia, considered and approved the audited Financial Results for the quarter and year ended 31<sup>st</sup> March, 2018.


Copy of audited Financial Results for the quarter and year ended 31<sup>st</sup> March, 2018, along with Statement of Assets and Liabilities and Audit Report is enclosed herewith.

Kindly take the same on record and acknowledge the receipt of the same.

Thanking You,  
for Vista Pharmaceuticals Limited

*Chalapathirao Venkata Naraparaju*

**Chalapathirao Venkata Naraparaju**  
**Wholtime Director**  
**DIN: 03270178**





# Vista Pharmaceuticals Ltd

CIN : L24239TG1991PLC012264

7-1-212/A/70, Plot No. : 85, Shivbagh, Ameerpet, Hyderabad-16. Telangana  
India Tel: 91-40-65581585, Fax : 91-40-23741585  
e-mail : admin.hyd@vistapharmaceuticals.com www.vistapharmaceuticals.com

Hyderabad, 30<sup>th</sup> May, 2018.

To  
The General Manager,  
Listing Department,  
Bombay Stock Exchange Limited,  
1<sup>st</sup> Floor, New Trading Wing,  
Rotunda Building, P.J. Towers,  
Dalal Street Fort,  
Mumbai-400001.

Dear Sirs/Madam,

**Subject:** Declaration pursuant to Regulation 33 (3) (d) of the Securities & Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2016.

## DECLARATION

I, Chalapathirao Venkata Naraparaju, Wholetime Director of the Vista Pharmaceuticals Limited (CIN: L24239TG1991PLC012264) having its Registered office at Plot Nos.10 TO 14 and 16 To 20, APIIC, Industrial Estate, Chityal, Gopalaipalli 508254, Telangana, India hereby declare that, the Statutory Auditors of the Company, M/s. MAHESH, VIRENDER & SRIRAM (FRN: 001939S), have issued an Audit Report with unmodified opinion on the annual Audited Financial Results of the Company for year ended on 31<sup>st</sup> March, 2018.


This Declaration is given in compliance to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended by the SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulation, 2016 vide notification No. SEBI/LAD-NRO/GN/2016-17/001 dated May 25, 2016 and Circular no. CIR/CFD/CMD/56/2016 dated May 27, 2016.

Kindly take this declaration on your records.

Yours Sincerely,

Thanking You,  
for Vista Pharmaceuticals Limited

**Chalapathirao Venkata Naraparaju**  
**Wholetime Director**  
**DIN: 03270178**





# Vista Pharmaceuticals Ltd

CIN : L24239TG1991PLC012264

7-1-212/A/70, Plot No. : 85, Shivbagh, Ameerpet, Hyderabad-16. Telangana

India Tel: 91-40-65581585, Fax : 91-40-23741585

e-mail : admin.hyd@vistapharmaceuticals.com www.vistapharmaceuticals.com

## VISTA PHARMACEUTICALS LIMITED


CIN:L24239TG1991PLC012264

### Audited financial results for the Quarter and Year ended 31.03.2018

(in Rs Lakhs)

S.No	Particulars	Quarter ended			Year ended	
		March 31,2018	December 31,2017	March 31,2017	March 31,2018	March 31,2017
		Audited	Un Audited	Audited	Audited	Audited
1	<b>Income</b>					
	a. Revenue from operations	710.78	711.59	611.53	2891.78	2418.19
	b. Other income	39.68	-	5.31	39.68	5.74
2	<b>Total Income (a+b)</b>	<b>750.46</b>	<b>711.59</b>	<b>616.84</b>	<b>2931.46</b>	<b>2423.93</b>
3	<b>Expenses</b>					
	a) Cost of Material Consumed	415.27	370.31	363.36	1596.27	1610.27
	b) Change in Inventories	-	-	-	-	-
	c) Employee benefits expense	33.98	26.68	31.49	105.40	87.65
	d) Finance costs	40.19	38.18	25.05	157.49	87.60
	e) Depreciation and amortization expense	22.49	56.04	23.80	133.56	101.51
	f) Other expenses	174.14	148.49	153.79	656.04	414.66
	<b>Total Expenses</b>	<b>686.08</b>	<b>639.70</b>	<b>597.48</b>	<b>2,648.77</b>	<b>2,301.68</b>
4	<b>Profit before tax (2-3)</b>	<b>64.38</b>	<b>71.89</b>	<b>19.36</b>	<b>282.69</b>	<b>122.25</b>
5	<b>Tax expense</b>					
	(1) Current tax	13.13	14.66	6.76	57.64	6.76
	(2) Deferred tax	(6.40)	(2.22)	(2.31)	6.41	(9.26)
6	<b>Net Profit for the Period (4-5)</b>	<b>57.66</b>	<b>59.45</b>	<b>14.92</b>	<b>218.65</b>	<b>124.75</b>
7	<b>Other comprehensive income (OCI)</b>					
	(a) (i) Items that will not be reclassified to profit or loss	-	-	-	-	-
	(ii) Tax on items that will not be reclassified to profit or loss	-	-	-	-	-
	(b) (i) Items that will be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
	<b>Total Other Comprehensive income</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
8	<b>Total Comprehensive income (6+7)</b>	<b>57.66</b>	<b>59.45</b>	<b>14.92</b>	<b>218.65</b>	<b>124.75</b>
	<b>Earnings per equity share</b> (Face value of Rs.10/- each)					
	(1) Basic	0.20	0.21	0.05	0.76	0.46
	(2) Diluted	0.19	0.20	0.05	0.73	0.46
	Paid- up equity share capital(Face Value of Rs.2/- each)	582.94	572.94	531.43	582.94	531.43

*M. Ch. S. S. R.*





# Vista Pharmaceuticals Ltd

CIN : L24239TG1991PLC012264

7-1-212/A/70, Plot No. : 85, Shivbagh, Ameerpet, Hyderabad-16. Telangana

India Tel: 91-40-65581585, Fax : 91-40-23741585


e-mail : admin.hyd@vistapharmaceuticals.com www.vistapharmaceuticals.com

**VISTA PHARMACEUTICALS LIMITED**  
**CIN:L24239TG1991PLC012264**  
**STATEMENT OF ASSETS AND LIABILITIES**

(Rs. In lakhs)

Particulars	(Rs. In lakhs)	
	As at 31st March 2018 (Audited)	As at 31st March 2017 (Audited)
<b>ASSETS</b>		
<b>Non-current assets</b>		
(a) Property, Plant and Equipment	1,193.16	976.20
(b) Capital work-in-progress	710.94	199.16
(c) Goodwill	-	-
(d) Other Intangible assets	573.65	369.66
(e) Financial Assets	-	-
(i) Investments	1.98	0.05
(ii) Loans	7.86	6.66
(iii) Other financial assets	-	-
(f) Tax Assets	28.74	59.64
(g) Other Non-Current Assets	-	0.64
<b>Total Non - Current Assets</b>	<b>2,516.33</b>	<b>1,612.01</b>
<b>Current assets</b>		
(a) Inventories	1,091.23	814.27
(b) Financial assets		
(i) Investments	-	-
(ii) Trade receivables	1,086.13	901.32
(iii) Cash and Bank equivalents	97.68	190.75
cash and cash equivalent (restricted cash)	81.10	383.28
(iv) Others	-	2.63
(c) Other current assets	427.67	257.98
<b>Total Current Assets</b>	<b>2,783.82</b>	<b>2,550.23</b>
<b>Total Assets</b>	<b>5,300.15</b>	<b>4,162.24</b>
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
(a) Equity Share capital	582.94	531.43
(b) Money received against warrants	556.93	-
(c) Other equity	2,045.87	1,129.48
<b>Total Equity</b>	<b>3,185.75</b>	<b>1,660.91</b>
<b>Liabilities</b>		
<b>Non-current liabilities</b>		
(a) Financial Liabilities		
(i) Borrowings	588.43	602.97
(ii) Other financial liabilities	-	-
(b) Deferred tax liabilities (Net)	-	-
(c) Long term Provisions	6.09	5.23
<b>Total Non - Current Liabilities</b>	<b>594.53</b>	<b>608.19</b>
<b>Current liabilities</b>		
(a) Financial Liabilities		
(i) Borrowings	518.02	530.43
(ii) Trade payables	918.06	1,303.44
(iii) Other financial liabilities	13.49	17.13
(b) Other current liabilities	12.66	17.64
(c) Provisions	57.64	24.50
<b>Total Current Liabilities</b>	<b>1,519.87</b>	<b>1,893.13</b>
<b>Total Liabilities</b>	<b>2,114.40</b>	<b>2,501.33</b>
<b>Total Equity and Liabilities</b>	<b>5,300.15</b>	<b>4,162.24</b>

*Handwritten signature*





# Vista Pharmaceuticals Ltd

CIN : L24239TG1991PLC012264

7-1-212/A/70, Plot No. : 85, Shivbagh, Ameerpet, Hyderabad-16. Telangana

India Tel: 91-40-65581585, Fax : 91-40-23741585

e-mail : admin.hyd@vistapharmaceuticals.com www.vistapharmaceuticals.com

## Notes to the Statement of financial Results

1. The financial results of the company have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under the companies (Indian Accounting standards) Rules, 2015 as amended by the companies (Indian Accounting standards) (Amendment) rules, 2016. The company adopted Ind As from 1st April 2017, and these are the company's first annual financial statements prepared in accordance with Indian Accounting Standards (Ind AS). The company has adopted all applicable standards and adoptions were carried out in accordance with Ind AS 101- First time adoption of Indian Accounting Standards.
2. Total Income for the current quarter is Rs.750.46 Lakhs compared to Rs.616.84 Lakhs for the corresponding quarter of the previous year. Total Income for the financial year ended 31st March 2018 is Rs.2931.46 Lakhs compared to Rs.2423.93 Lakhs for the previous year.
3. The Profit before tax for the current quarter is Rs. 64.38 Lakhs compared to Rs. 19.35 Lakhs for the corresponding quarter of the previous year. The Profit before tax for the financial year ended 31st March 2018 is Rs. 282.69 Lakhs compared to Rs. 122.26 Lakhs for the previous year.
4. The Profit/(Loss) After tax for the current quarter is Rs.57.66 Lakhs compared to Rs.14.90 Lakhs for the corresponding quarter of the previous year. The Profit/(Loss) after tax for the financial year ended 31st March 2018 is Rs.218.65 Lakhs compared to Rs.124.76 Lakhs for the previous year.
5.
  - a) Reconciliation between Standalone financial results, as previously reported (referred as Previous GAAP) and IND AS for the quarter and Financial year ended 31st March 2017 as under

	Quarter ended 31st March 2017	Year ended 31st March 2017
Particulars	(Audited)	(Audited)
<b>Net profit as per Previous GAAP</b>	<b>10.07</b>	<b>115.14</b>
a) Impact on account of measuring long term borrowings using effective rate of Interest	8.08	8.08
b) Impact on account of Expected Credit Loss	(0.61)	(0.94)
c) Items considered as amortisation expense in the P& L as per previous GAAP already adjusted in opening equity as on the transition to IND AS.	1.81	2.48
d) Impact on account of Current & Deferred Taxes	(4.45)	(0.01)
<b>Net profit as per IND AS</b>	<b>14.90</b>	<b>124.75</b>
a) Impact on account of measuring investments at fair value through OCI		
<b>Total Comprehensive Income under IND AS</b>	<b>14.90</b>	<b>124.75</b>

- b) Reconciliation between Total Equity, as previously reported (referred as Previous GAAP) and IND AS for the quarter and Financial year ended 31st March 2017 and 1st April 2016 as under

	Equity as at 31st March 2017	Equity as at 1st April 2016
Particulars	(Audited)	(Audited)
<b>Equity as per Previous GAAP</b>	<b>1,614.03</b>	<b>1,121.00</b>
Items not qualified as asset as per IND AS	-9.93	-9.93
Impact on account of deferred Tax	50.38	50.39
Impairment of Receivables	-4.13	(3.19)
Items considered as amortisation expense in the P& L as per previous GAAP already adjusted in opening equity as on the transition to IND	2.48	-
Impact on account of measuring long term borrowings using effective rate of Interest	8.08	
<b>Equity as per IND AS</b>	<b>1660.91</b>	<b>1158.26</b>

*Handwritten signature*







# Vista Pharmaceuticals Ltd

CIN : L24239TG1991PLC012264

7-1-212/A/70, Plot No. : 85, Shivbagh, Ameerpet, Hyderabad-16. Telangana


India Tel: 91-40-65581585, Fax : 91-40-23741585

e-mail : admin.hyd@vistapharmaceuticals.com www.vistapharmaceuticals.com

6. The Company concluded that there is only one operating segment i.e, Manufacturing of Pharmaceutical products and the same becomes only one operating and reportable segment the Company. Accordingly, the Company shall present entity-wide disclosures enumerated in paragraphs 32, 33 and 34 of Ind AS 108.
7. The aforementioned results are reviewed by the Audit Committee of the Board and subsequently taken on record by the board of directors at its meeting held on 30th May , 2018. The statement included the results for the quarter ended 31st March 2018 and 31st March 2017 being the balancing figure of the audited figures in respect of the full financial year and the published year to date figures upto the third quarter of the respective financial years, which were subject to limited review by the respective auditors
8. The results for the year ended 31st March 2018 are also available on the bomabay stock exchange website, the National Stock exchange website and on the Company's website
9. The company is acquiring a complex ANDA for UROCARE and its US market size is USD 1.3 billion (Rs 8,840 Crores) as per the latest IMS data.
10. The company already filed a complex ANDA in September 2017, targeting Cardialgy segment with a US market size of USD 200 million (Rs 1,360 Crores) as per latest IMS data.

Place:Hyderabad

Date:26.05.2018



For Vista Pharmaceuticals Limited

*N.V. Chalapathi Rao*  
N.V. Chalapathi Rao  
Whole Time Director